> A team of chemists from UCB's recently closed research facility at Cambridge, England are being transferred to a service division of Galapagos to work under a contract that could be worth up to 4 million euros. Report
> Australia's Acrux and KV Pharmaceuticals have agreed to swap late-stage data in exchange for drug delivery technology. Acrus says the deal will help win early approvals around the world for its therapy for menopause symptoms. Report
> The FDA has paved the way for Gilead Sciences to expand use of its AIDS drug Viread to include hepatitis B. Viread racked up about $613 million last year. Report
> The FDA has granted a priority review for a new pain therapy--Remoxy--from Pain Therapeutics and King Pharmaceuticals. Story
> BioTime has licensed stem cell technology from Advanced Cell Technology. Report
> Australian scientists, who have been studying a key protein that controls the spread of blood cancer cells when it is damaged, are now designing a drug they say can stop the cancer--along with asthma and other inflammatory diseases such as rheumatoid arthritis. Report
> For the first time, scientists at Albert Einstein College of Medicine have been able to prevent the age-related decline of the liver--a process that could have significant implications for preventing a host of age-related ailments like Parkinson's and Alzheimer's. Report
> California's stem cell boom has spurred a research hiring bonanza. Report
> If you're wondering how GlaxoSmithKline's sales-and-marketing team is doing, we might have the answer. Blogger Jim Edwards looks at GSK's yield on its marketing dollars and finds that they're "just about treading water." Report
> A criminal price-fixing trial in the U.K. against several generics makers has fallen apart. But that hasn't stopped the government from trying to collect damages. Report
> Fighting lawsuits is bad enough. After all, the pharma business is full of them: patent fights, product liability cases, regulatory disputes. Now, the Financial Accounting Standards Board--the accounting organization that sets the rules for companies' numbers-reporting--wants businesses to regularly disclose how much various lawsuits will cost them. Report
Industry Voices: The future of drug development. Article
And Finally... What's the real value of drug research? The Scientist analyzed the payoffs earned by success in the drug development field these days. Report